Our ophthalmic study is a signature specialty of West China-Frontier PharmaTech. Our ophthalmologists collaborate
extensively with the ophthalmology department of the West China Hospital. Our lab has 4 well experienced study directors and 3 senior specialists who have conducted pre-clinic studies on ophthalmic medication or intraocular implantable biomaterials for over 10 years.
The lab has state-of-the-art instruments: Retinal camera and color photograph imaging system, fluorescein fundus
angiography, laser photocoagulator, electro-physiological diagnostic systems, optical coherence tomography (OCT),
So far, the lab has conducted pre-clinic studies on 22 ophthalmic medications (macromolecular, small molecule or nucleic acid), of which 1 has come to market, 2 have obtained clinical approval, 9 have finished pre-clinical safety study and filed for clinical approval, 8 are under-going pre-clinical safety studies. Indications include age-related macular degeneration (AMD), uveitis and vitreum adhesion.